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INTRODUCTION
• Endocrine therapies and cdk4/6 inhibitors have 
improved clinical outcomes and progression-
free survival in metastatic hormone receptor 
positive (HR+), human epidermal growth factor 
2 negative (HER2-) breast cancers (1).
• Early-stage breast cancer patients benefit 
initially from endocrine therapies, but most 
breast cancers eventually develop de novo or 
acquired resistance to cdk4/6i (2, 3). 
• Mechanisms of cdk4/6i resistance in HR+ 
breast cancers are due mainly to endocrine 
therapy insensitivity (4).
• Multiple pathways involved in the development 
of resistance have been identified. However,
Improved clinical outcomes remain largely 
limited after development of resistance and 
disease progression.
• Focusing on clinical biomarkers contributing to 
resistance helps identify disease progression.
• Interleukin-6 promotes tumor survival and 
progression and could be investigated as a 
potential biomarker.
HYPOTHESIS
IL-6, a potential biomarker for endocrine therapy 
resistance, can be used to predict response to 
endocrine therapies in HR+, HER2- breast 
cancers. As an upregulator for tumor survival, IL-6 
levels will increase during disease progression. 
Investigation into biomarkers will help determine 
additional therapies and give a better indication of 
metastatic HR+, HER2- breast cancer treatment 
response to cdk4/6i. 
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FIGURE 1
MATERIALS & METHODS
• Reagents: R&D Systems Quantikine Human 
IL-6 ELISA kit
• Patient Samples: Blood drawn from HR+, 
HER2- breast cancers at certain treatment 
timepoints and obtained through the clinic
• ELISA: Extracted plasma from patient blood 
samples to detect IL-6 levels throughout 
treatment timepoints
Additional Details:
• Blood samples were drawn from patients at 
baseline, timepoints at months 1, 4, 8, 12 into 
cdk4/6i treatment, and at progression
A
Matched IL-6 Quantification
Figure 1. (A) Biospecimen collection was prospectively planned and collected 
from patients consented to the study at baseline, on treatment cdk4/6i timepoints 
at months 1, 4, 8, 12, and progression. Biospecimens collected included blood, 
serum, plasma, peripheral blood mononuclear cells (PBMCs), and circulating 
tumors cells (CTCs). (B) IL-6 was quantified through ELISA on patient plasma, 
where plasma was obtained by centrifugation of blood samples and collection of 
the resulting top-most layer. IL-6 levels were matched to their respective patients 
that had available blood samples at pre and post cdk4/6i timepoints.
Unmatched IL-6 Quantification
On Treatment IL-6 Levels
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Figure 2. IL-6 measurements from all HR+, HER2- breast cancer patients 
enrolled in the study were categorized and compiled based on non-metastatic 
early stage, pre cdk4/6i metastatic, and post cdk4/6i metastatic breast cancer 
status. Error bars represent SEM. The asterisks and hash symbols indicate 
significant differences in plasma IL-6 levels among the breast cancer stages.
FIGURE 2
FIGURE 3
Figure 3. IL-6 levels obtained through ELISA on plasma samples from 
metastatic HR+, HER2- breast cancer patients currently on cdk4/6i 
treatment were plotted. Patients were identified by PA and study number 
in order instead of medical record numbers for HIPAA compliance.
RESULTS & DISCUSSION
Ø Of the patients in the study who progressed, IL-6 levels at 
progression for those patients were higher than the IL-6 
levels at baseline, even when IL-6 on-treatment trends 
were variable across patients 
Ø Upon compiling all IL-6 measurements from metastatic or 
non-metastatic patients at baseline or progression, IL-6 
levels in HR+, HER2- metastatic breast cancer patients 
who have progressed (post cdk4/6i) are significantly higher 
than IL-6 levels in metastatic patients at baseline (pre 
cdk4/6i) or early-stage non-metastatic patients.
Ø In addition, metastatic patients at baseline have 
significantly higher IL-6 plasma levels than the IL-6 levels 
of non-metastatic early-stage breast cancer patients.
Ø IL-6 levels did not exhibit significant change in on-
treatment stages where the tumor was stable and had not 
yet developed therapeutic resistance.
Ø The sharp, significant increase in IL-6 levels during 
progression compared to baseline strongly suggests IL-6 is 
an important biomarker for resistance to endocrine 
therapies in HR+, HER2- breast cancers.
Ø Further focus on IL-6 and other potential biomarkers 
contributing to resistance would help better identify and 
predict disease progression, allowing determination of 
additional therapies and improved clinical outcomes.
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